X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Lead Product(s): ET-101
Therapeutic Area: Neurology Product Name: ET-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Forge Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 29, 2022
Details:
The company’s 1st-in-class gene therapy ET-101 has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function.
Lead Product(s): ET-101
Therapeutic Area: Neurology Product Name: ET-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
Funding will support Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.
Lead Product(s): L-ICON3
Therapeutic Area: Oncology Product Name: L-ICON3
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CincyTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing June 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
